Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

59.61 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	5
Open	59.61
Bid (Size)	39.50 (100)
Ask (Size)	95.37 (200)
Prev. Close	59.61
Today's Range	59.61 - 59.61
52wk Range	55.17 - 170.87
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

March 11, 2026

From GeneDx

Via Business Wire

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

March 10, 2026

Ark Invest's CEO kicked off the new trading week with a little shopping.

Via The Motley Fool

Performance

YTD	-54.9%	-54.9%
1 Month	-19.7%	-19.7%
3 Month	-53.9%	-53.9%
6 Month	-47.7%	-47.7%
1 Year	-32.7%	-32.7%

More News

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

March 10, 2026

From GeneDx

Via Business Wire

GeneDx Holdings Corp (NASDAQ:WGS) Reports Mixed Q4 2025 Results, Stock Falls Despite Strong 2026 Outlook ↗

February 23, 2026

Via Chartmill

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

March 09, 2026

From GeneDx

Via Business Wire

Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million ↗

February 27, 2026

Via The Motley Fool

Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗

February 27, 2026

Via The Motley Fool

What a $75 Million Exit From MDU Might Signal Amid a 24% One-Year Rally ↗

February 26, 2026

Via The Motley Fool

GeneDx's Chief Operating Officer Sold Nearly 6,000 Shares. Is the Stock a Buy or Sell? ↗

February 26, 2026

Via The Motley Fool

GeneDx to Participate in Upcoming Investor Conferences

February 25, 2026

From GeneDx

Via Business Wire

GeneDx (WGS) Q4 2025 Earnings Call Transcript ↗

February 23, 2026

Via The Motley Fool

INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

February 23, 2026

From GeneDx

Via Business Wire

Power Solutions Stock Up 140% as $6.36 Million Exit Follows 62% Sales Surge ↗

February 16, 2026

Via The Motley Fool

Freshworks Falls 60% in a Year as $7.5 Million Sale Shrinks Stake to 3.1% of This Portfolio's Assets ↗

February 16, 2026

Via The Motley Fool

Air Lease Stock Up 43% as Investor Trims $6.9 Million Stake Despite $1 Billion Profit Year ↗

February 16, 2026

Via The Motley Fool

Five9 Stock Down 60% This Past Year, but One Investor Just Lifted Stake With $3.5 Million Buy ↗

February 16, 2026

Via The Motley Fool

Freshworks Stock Down 60% in One Year as Revenue Jumps 16% and One Investor Sells $7 Million in Shares ↗

February 16, 2026

Via The Motley Fool

TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World’s Most Influential Leaders in Health

February 11, 2026

From GeneDx

Via Business Wire

GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026

February 03, 2026

From GeneDx

Via Business Wire

The Great Rotation: Small-Caps Stand Tall as AI Exhaustion Triggers Tech Rout

January 29, 2026

Via MarketMinute

The Great Rotation of 2026: Why Wall Street is Abandoning Big Tech for Main Street Small Caps

January 28, 2026

Via MarketMinute

The Great AI Pivot: From Massive Build-Out to the Era of Operational ROI

January 27, 2026

Via MarketMinute

The Great Rotation: Wall Street’s ‘Earnings Handoff’ Moves from Silicon Valley to Main Street

January 26, 2026

Via MarketMinute

The Great Rotation: Small-Caps Set to Outpace ‘Magnificent 7’ in Historic Earnings Handoff

January 26, 2026

Via MarketMinute

Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗

January 25, 2026

Via The Motley Fool

Frequently Asked Questions

Is GeneDx Holdings Corp. - Class A Common Stock publicly traded?

Yes, GeneDx Holdings Corp. - Class A Common Stock is publicly traded.

What exchange does GeneDx Holdings Corp. - Class A Common Stock trade on?

GeneDx Holdings Corp. - Class A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for GeneDx Holdings Corp. - Class A Common Stock?

The ticker symbol for GeneDx Holdings Corp. - Class A Common Stock is WGS on the Nasdaq Stock Market

What is the current price of GeneDx Holdings Corp. - Class A Common Stock?

The current price of GeneDx Holdings Corp. - Class A Common Stock is 59.61

When was GeneDx Holdings Corp. - Class A Common Stock last traded?

The last trade of GeneDx Holdings Corp. - Class A Common Stock was at 03/30/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.